1
|
Abawi A, Trunfio-Sfarghiu AM, Thomann C, Petiot E, Lollo G, Granjon T, Girard-Egrot A, Maniti O. Tailor-made vincristine-liposomes for tumor targeting. Biochimie 2024:S0300-9084(24)00176-7. [PMID: 39094823 DOI: 10.1016/j.biochi.2024.07.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Revised: 07/22/2024] [Accepted: 07/30/2024] [Indexed: 08/04/2024]
Abstract
To ensure selective targeting based on membrane fluidity and physico-chemical compatibility between the biological membrane of the target cell and the lipid membrane of the liposomes carriers. Lipid-based carriers as liposomes with varying membrane fluidities were designed for delivering vincristine, an anti-tumor compound derived from Madagascar's periwinkle. Liposomes, loaded with vincristine, were tested on prostate, colon, and breast cancer cell lines alongside non-tumor controls. Results showed that vincristine-loaded liposomes with fluid membranes significantly decreased the viability of cancer cell lines compared to controls. Confocal microscopy revealed the intracellular release of vincristine, evidenced by disrupted mitosis-specific labeling of actin filaments in metastatic prostate cell lines. This highlights the crucial role of membrane fluidity in the development of lipid-based drug carriers, offering a promising and cost-effective option for targeting cancer cells as an alternative to conventional strategies.
Collapse
Affiliation(s)
- Ariana Abawi
- Institute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, Univ. Lyon, University Lyon 1, CNRS, 69622, Lyon, France.
| | | | - Céline Thomann
- Institute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, Univ. Lyon, University Lyon 1, CNRS, 69622, Lyon, France.
| | - Emma Petiot
- Institute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, Univ. Lyon, University Lyon 1, CNRS, 69622, Lyon, France.
| | - Giovanna Lollo
- Laboratoire D'Automatique, de Génie des Procédés et de Génie Pharmaceutique, LAGEPP UMR 5007, University Lyon 1, CNRS, 69622, Lyon, France.
| | - Thierry Granjon
- Institute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, Univ. Lyon, University Lyon 1, CNRS, 69622, Lyon, France.
| | - Agnès Girard-Egrot
- Institute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, Univ. Lyon, University Lyon 1, CNRS, 69622, Lyon, France.
| | - Ofelia Maniti
- Institute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, Univ. Lyon, University Lyon 1, CNRS, 69622, Lyon, France.
| |
Collapse
|
2
|
Liu C, Hu Y, Lin J, Fu H, Lim LY, Yuan Z. Targeting strategies for drug delivery to the kidney: From renal glomeruli to tubules. Med Res Rev 2018; 39:561-578. [DOI: 10.1002/med.21532] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2018] [Revised: 07/10/2018] [Accepted: 07/18/2018] [Indexed: 12/22/2022]
Affiliation(s)
- Chun‐Ping Liu
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - You Hu
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - Ju‐Chun Lin
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - Hua‐Lin Fu
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - Lee Yong Lim
- Pharmacy, Centre for Optimization of Medicines, School of Allied Health, The University of Western AustraliaCrawley Australia
| | - Zhi‐Xiang Yuan
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| |
Collapse
|
3
|
Anwar M, Akhter S, Mallick N, Mohapatra S, Zafar S, Rizvi MMA, Ali A, Ahmad FJ. Enhanced anti-tumor efficacy of paclitaxel with PEGylated lipidic nanocapsules in presence of curcumin and poloxamer: In vitro and in vivo studies. Pharmacol Res 2016; 113:146-165. [DOI: 10.1016/j.phrs.2016.08.025] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Revised: 06/01/2016] [Accepted: 08/18/2016] [Indexed: 10/21/2022]
|
4
|
Saleem Q, Zhang Z, Gradinaru CC, Macdonald PM. Liposome-coated hydrogel spheres: delivery vehicles with tandem release from distinct compartments. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2013; 29:14603-14612. [PMID: 24156402 DOI: 10.1021/la402796k] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
We have fabricated unilamellar lipid bilayer VESicle-COated hydrogel spheres (VESCOgels) by carbodiimide-mediated coupling of liposomes bearing surface amines to core-shell hydrogel spheres bearing surface carboxyls. The amine-containing moiety, 3-O (2-aminoethoxyethyloxyethyl)carbamyl cholesterol (AECHO), was incorporated into large unilamellar vesicles (LUVs), diameter ∼100 nm, composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC). The hydrogel, diameter ∼ 1 μm, consisted of a core of poly(N-isopropyl acrylamide) (pNIPAM) and a shell of p(NIPAM-co-acrylic acid (AA)). Activation of these surface-displayed carboxyls with N-hydroxysuccinimidyl (NHS) esters permitted amine coupling upon addition of AECHO-containing POPC LUVs. Bilayer integrity of the hydrogel-bound LUVs was maintained, and fusion of LUVs did not occur. Fluorescence assays of the release of cobalt-calcein trapped within hydrogel-bound LUVs and of sodium fluorescein trapped within the hydrogel itself showed that each compartment retained its distinct release attributes: fast release from the microgel and slow release from the LUVs. It is envisioned that VESCOgels will be useful, therefore, in applications requiring temporally controlled delivery of distinct drugs.
Collapse
Affiliation(s)
- Qasim Saleem
- Department of Chemistry and ‡Department of Physics, University of Toronto , Toronto, Ontario, Canada
| | | | | | | |
Collapse
|
5
|
Shukla AK, Patra S, Dubey VK. Nanospheres encapsulating anti-leishmanial drugs for their specific macrophage targeting, reduced toxicity, and deliberate intracellular release. Vector Borne Zoonotic Dis 2012; 12:953-60. [PMID: 22925019 DOI: 10.1089/vbz.2011.0948] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The current work focuses on the study of polymeric, biodegradable nanoparticles (NPs) for the encapsulation of doxorubicin and mitomycin C (anti-leishmanial drugs), and their efficient delivery to macrophages, the parasite's home. The biodegradable polymer methoxypoly-(ethylene glycol)-b-poly (lactic acid) (MPEG-PLA) was used to prepare polymeric NPs encapsulating doxorubicin and mitomycin C. The morphology, mean diameter, and surface area of spherical NPs were determined by transmission electron microscopy (TEM), field emission scanning electron microscopy (FESEM), and BET surface area analysis. X-ray diffraction was performed to validate drug encapsulation. An in vitro release profile of the drugs suggested a fairly slow release. These polymeric NPs were efficiently capable of releasing drug inside macrophages at a slower pace than the free drug, which was monitored by epi-fluorescence microscopy. Encapsulation of doxorubicin and mitomycin C into NPs also decreases cellular toxicity in mouse macrophages (J774.1A).
Collapse
Affiliation(s)
- Anil Kumar Shukla
- Department of Biotechnology, Indian Institute of Technology Guwahati, Guwahati, Assam, India
| | | | | |
Collapse
|
6
|
Zhang XX, McIntosh TJ, Grinstaff MW. Functional lipids and lipoplexes for improved gene delivery. Biochimie 2011; 94:42-58. [PMID: 21621581 DOI: 10.1016/j.biochi.2011.05.005] [Citation(s) in RCA: 89] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2011] [Accepted: 05/06/2011] [Indexed: 12/17/2022]
Abstract
Cationic lipids are the most common non-viral vectors used in gene delivery with a few currently being investigated in clinical trials. However, like most other synthetic vectors, these vectors suffer from low transfection efficiencies. Among the various approaches to address this challenge, functional lipids (i.e., lipids responding to a stimuli) offer a myriad of opportunities for basic studies of nucleic acid-lipid interactions and for in vitro and in vivo delivery of nucleic acid for a specific biological/medical application. This manuscript reviews recent advances in pH, redox, and charge-reversal sensitive lipids.
Collapse
Affiliation(s)
- Xiao-Xiang Zhang
- Department of Chemistry, Boston University, Boston, MA 02215, USA
| | | | | |
Collapse
|
7
|
Hwang SY, Cho DY, Kim HK, Cho SH, Choo J, Yoon WJ, Lee EK. Preparation of Targeting Proteoliposome by Postinsertion of a Linker Molecule Conjugated with Recombinant Human Epidermal Growth Factor. Bioconjug Chem 2010; 21:345-51. [DOI: 10.1021/bc9004409] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Sang Youn Hwang
- Department of Chemical Engineering, Department of Bionanotechnology, and Department of Applied Chemistry, Hanyang University, Ansan, 425-791 Korea, and College of Bionanotechnology, Kyungwon University, Seongnam, Korea 461-701
| | - Do Youn Cho
- Department of Chemical Engineering, Department of Bionanotechnology, and Department of Applied Chemistry, Hanyang University, Ansan, 425-791 Korea, and College of Bionanotechnology, Kyungwon University, Seongnam, Korea 461-701
| | - Hak Kyoung Kim
- Department of Chemical Engineering, Department of Bionanotechnology, and Department of Applied Chemistry, Hanyang University, Ansan, 425-791 Korea, and College of Bionanotechnology, Kyungwon University, Seongnam, Korea 461-701
| | - Seung Hun Cho
- Department of Chemical Engineering, Department of Bionanotechnology, and Department of Applied Chemistry, Hanyang University, Ansan, 425-791 Korea, and College of Bionanotechnology, Kyungwon University, Seongnam, Korea 461-701
| | - Jaebum Choo
- Department of Chemical Engineering, Department of Bionanotechnology, and Department of Applied Chemistry, Hanyang University, Ansan, 425-791 Korea, and College of Bionanotechnology, Kyungwon University, Seongnam, Korea 461-701
| | - Won Joong Yoon
- Department of Chemical Engineering, Department of Bionanotechnology, and Department of Applied Chemistry, Hanyang University, Ansan, 425-791 Korea, and College of Bionanotechnology, Kyungwon University, Seongnam, Korea 461-701
| | - E. K. Lee
- Department of Chemical Engineering, Department of Bionanotechnology, and Department of Applied Chemistry, Hanyang University, Ansan, 425-791 Korea, and College of Bionanotechnology, Kyungwon University, Seongnam, Korea 461-701
| |
Collapse
|
8
|
Abstract
Shortly after the discovery of liposomes (J Mol Biol 13:238-252, 1965), Gregoriadis et al. (Lancet 1:1313-1316, 1974) suggested their use as drug delivery vesicles. Since then there have been many developments in liposomal composition, efficient drug encapsulation and retention, stability, and targeting (Biochim Biophys Acta 1113:171-199, 1992). However, even though some of the very potent drug formulations in liposomes were clinically approved, in most cases the amount of drug passively released from such ideal, long-circulating, sterically stable liposomes was not enough to show a therapeutic effect (Cancer Chemother Pharmacol 49:201-210, 2002; Cancer Chemother Pharmacol 48:266-268, 2001; Eur J Cancer 37:2015-2022, 2001; Breast Cancer Res Treat 77:185-188, 2003; Lung Cancer 34:427-432, 2001; Cancer Chemother Pharmacol 50:131-136, 2002). It has been hypothesized that the enhanced release at the target site will significantly improve the specificity and efficacy of a liposomal drug (J Liposomes Res 8:299-335, 1998; Pharmaco Rev 51:691-744, 1999; Curr Opin Mol Ther 3:153-158, 2001). To solve this challenge, more research efforts were directed toward a triggered release, in response to a specific stimulus at a target site. Here, we present an engineered, bacterial channel protein as a remote-controlled nanovalve in sterically stable liposomes for a triggered release of the liposomal content on command.
Collapse
Affiliation(s)
- Armagğan Koçer
- Department of Biochemistry, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, The Netherlands
| |
Collapse
|
9
|
Koçer A. A Remote Controlled Valve in Liposomes for Triggered Liposomal Release. J Liposome Res 2008; 17:219-25. [DOI: 10.1080/08982100701528203] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Lundberg BB, Griffiths G, Hansen HJ. Cellular Association and Cytotoxicity of Doxorubicin-Loaded Immunoliposomes Targeted via Fab' Fragments of an Anti-CD74 Antibody. Drug Deliv 2008; 14:171-5. [PMID: 17454037 DOI: 10.1080/10717540601036831] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
The purpose of our research was to evaluate in vitro therapeutic efficacy of doxorubicin (DXR)-loaded immunoliposomes with Fab' fragments of the anti-CD74 antibody LL1 attached to the surface. LL1 is well suited for targeting purposes because it is internalized very fast by B-lymphoma cells. However, at in vivo application whole antibodies show fast clearance in circulation. Taking this fact into consideration, this study was initiated to elucidate the prospects of using Fab' fragments of LL1 in stead of the whole antibody for future targeting in vivo of DXR-loaded liposomes. The Fab' fragments were covalently attached to the surface of sterically stabilized liposomes by use of a PEG-based heterobifunctinal coupling agent. LL1 Fab' conjugated sterically stabilized DXR liposomes showed approximately six times faster accumulation of the drug in Raji human B-lymphoma cells than nontargeted liposomes. In vitro cytotoxicity, quantitated by a tetrazolium assay, against Raji cells gave IC(50) values of 0.13, 0.45, and 0.11 microM for DXR-loaded immunoliposomes, DXR-loaded liposomes and free drug, respectively. The results from this study suggest that DXR-loaded immunoliposomes targeted with Fab' fragments from the anti-CD74 antibody LL1 could be a useful system for future in vivo experiments.
Collapse
Affiliation(s)
- B B Lundberg
- Department of Biochemistry and Pharmacy, Abo Akademi University, Abo, Finland.
| | | | | |
Collapse
|
11
|
Webb MS, Sarris AH, Cabanillas F, Mayer LD, Bally MB, Burge C, Cullis PR. Clinical and Preclinical Pharmacology of Liposomal Vincristine. J Liposome Res 2008. [DOI: 10.3109/08982100009031114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
12
|
Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 2007; 120:169-77. [PMID: 17586082 DOI: 10.1016/j.jconrel.2007.05.011] [Citation(s) in RCA: 180] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2006] [Revised: 04/18/2007] [Accepted: 05/05/2007] [Indexed: 11/26/2022]
Abstract
A sterically stabilized paclitaxel-loaded liposome tailored to target human breast cancer cells was developed, thereby promoting the efficiency of intracellular delivery of paclitaxel through receptor-mediated endocytosis. Results indicated that the targeting moiety (thiolated Herceptin) was successfully coupled to the distal reactive maleimide terminus of the poly (ethylene glycol)-phospholipid conjugate as well as being incorporated in the liposomal bilayers. The particle size of the PEGylated immunoliposome was maintained at about 200 nm. Confocal microscopy studies showed that the PEGylated immunoliposome was uptaken into the interior of the tumor cell through the receptor-mediated endocytosis pathway. The PEGylated immunoliposome showed substantially higher cellular uptake than the PEGylated liposome in cancer cells (BT-474 and SK-BR-3) over-expressing human epidermal growth factor receptor 2 (HER2) at 37 degrees C, while no difference was found in low HER2 expressing cells (MDA-MB-231) nor at low temperature (4 degrees C). Pharmacokinetics of paclitaxel in the PEGylated immunoliposome was compared with that in Taxol and in the PEGylated liposome in rats. The circulating time of paclitaxel in the PEGylated immunoliposome was prolonged compared to Taxol while slightly shortened than that in the PEGylated liposome. Therefore, the paclitaxel-loaded PEGylated immunoliposome using Herceptin could serve as a promising model for future tumor specific cancer therapy of HER2 over-expressing breast cancers.
Collapse
Affiliation(s)
- Tao Yang
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | | | | | | | | | | | | |
Collapse
|
13
|
Morimoto K, Kondo M, Kawahara K, Ushijima H, Tomino Y, Miyajima M, Kimura J. Advances in Targeting Drug Delivery to Glomerular Mesangial Cells by Long Circulating Cationic Liposomes for the Treatment of Glomerulonephritis. Pharm Res 2007; 24:946-54. [PMID: 17372685 DOI: 10.1007/s11095-006-9213-0] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2006] [Accepted: 12/11/2006] [Indexed: 11/30/2022]
Abstract
PURPOSE Newly designed polyethylene glycol (PEG)-modified cationic liposomes, containing a novel cationic lipid TRX-20 (3,5-dipentadecyloxybenzamidine hydrochloride), bind specifically to cultured human mesangial cells, and not to endothelial cells. In this study, we investigated targeting the delivery of PEG-modified liposomes containing TRX-20 (TRX-liposomes) to mesangial cells and evaluated their pharmacokinetic behavior in a rat experimental glomerulonephritis model, using prednisolone phosphate (PSLP) as a model drug. MATERIAL AND METHODS TRX-liposomes were injected intravenously into experimental glomerulonephritic rats and normal rats to compare its pharmacokinetic behavior with that of non-cationic liposomes (PEG-liposomes). Rhodamine-labeled liposomes were used to evaluate the accumulation in inflamed kidneys. Pharmacological effects of three formulations of PSLP (i.e., a single injection of two liposomal formulations and daily injections of PSLP in saline solution) were estimated in terms of suppressing glomerular cell proliferation in the rat nephritis model. RESULTS TRX-liposomes markedly accumulated in the glomeruli of inflamed kidneys, but did not accumulate in the glomeruli of normal kidneys. Although the PEG-liposomes also accumulated in the glomeruli of the inflamed kidneys, their pharmacological behavior was quite different from that of the TRX-liposomes, which were internalized by the target cells. In a comparison among the three formulations of PSLP, the dose of TRX-liposomes required for significant suppression of glomerular cell proliferation was much less (dose of 0.032 mg/kg and above) than that required for the same effect by the PSLP saline solution (3.2 mg/kg daily; 12.8 mg/kg total) and PEG-liposomes (0.32 mg/kg). Interestingly, significant suppression of mesangial cell activation, as assessed by the expression of alpha-smooth muscle actin, was observed in nephritic rats treated with TRX-liposomes, but not in the other two treatment groups. CONCLUSIONS The pharmaceutical properties of TRX-liposomes due to their preferential binding to mesangial cells and long circulation time make this a likely candidate system for targeted drug delivery to the inflamed glomeruli of glomerulonephritis.
Collapse
Affiliation(s)
- Katsumi Morimoto
- Research and Development Center, Terumo co., 1500 Inokuchi, Ashigarakami-gun, Kanagawa, 259-0151, Japan.
| | | | | | | | | | | | | |
Collapse
|
14
|
Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, Bally MB. Copper–topotecan complexation mediates drug accumulation into liposomes. J Control Release 2006; 114:78-88. [PMID: 16842880 DOI: 10.1016/j.jconrel.2006.05.019] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2006] [Revised: 05/11/2006] [Accepted: 05/24/2006] [Indexed: 11/20/2022]
Abstract
These studies describe the role of transition metal ions in the liposomal encapsulation of topotecan. Liposomes (1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and cholesterol (CH) (55:45, mole ratio)) were prepared with manganese (Mn), copper (Cu), zinc (Zn) or cobalt (Co) ion gradients (metal inside). Subsequently, topotecan was added to the liposome exterior (final drug-to-lipid ratio (mol/mol) of 0.2) and drug encapsulation was measured as a function of time and temperature. No drug loading was achieved with liposomes containing Co or Zn. Topotecan could be encapsulated into Mn-containing liposomes only in the presence of the ionophore, A23187 suggesting that a transmembrane pH gradient was necessary. However, Cu-containing liposomes, in the presence or absence of an imposed pH gradient, efficiently encapsulated topotecan. It has been reported that Cu(II) can form transition metal complexes with camptothecin; therefore, the Cu-topotecan interaction was characterized in solution as a function of pH. These investigations demonstrated that topotecan inhibited formation of an insoluble Cu hydroxide precipitate. Cryo-TEM analysis of the topotecan-loaded Cu liposomes showed electron-dense intravesicular precipitates. Further studies demonstrated that only the active lactone form of the drug was encapsulated and this form predominated in Cu-containing liposomes. Copper complexation reactions define a viable methodology to prepare liposomal camptothecin formulations.
Collapse
Affiliation(s)
- Amandeep S Taggar
- Department of Advanced Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave., Vancouver, BC, Canada V5Z 1L3
| | | | | | | | | | | | | |
Collapse
|
15
|
Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Kirpotin DB, Benz CC. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res 2005; 11:3392-401. [PMID: 15867240 DOI: 10.1158/1078-0432.ccr-04-2445] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
ErbB2-overexpressing human cancers represent potentially sensitive targets for therapy by candidate histone deacetylase (HDAC) inhibitors as we have shown that HDAC inhibitors can selectively reduce ErbB2 expression by repressing the ErbB2 promoter and accelerating the decay of cytoplasmic ErbB2 transcripts. To extend these in vitro findings and enhance the in vivo pharmacodynamic properties of HDAC inhibitors, we stably encapsulated a potent hydroxamate-based HDAC inhibitor (LAQ824) within long-circulating liposomes (Ls-LAQ824) and immunoliposomes (ILs-LAQ824) bearing >10,000 LAQ824 molecules per nanovesicle. Liposomal LAQ824 exhibits prolonged in vivo stability and, unlike free LAQ824, circulates with a half-life of 10.8 hours following a single i.v. injection. Three weekly i.v. injections of 20 to 25 mg/kg Ls-LAQ824 in nude mice with ErbB2 overexpressing BT-474 breast tumor xenografts significantly impairs tumor growth, and administration of ErbB2-targeted ILs-LAQ824 may further improve this antitumor activity. Studies of tumor-bearing mice 24 hours after single treatment indicate that: (a) >10% of injected liposomal LAQ824 is still circulating (whereas free LAQ824 is undetectable in the blood after 15 minutes); and (b) tumor uptake of Ls-LAQ824 and ILs-LAQ824 is >3% injected drug per gram of tumor, producing levels of acetylated tumor histones that are 5- to 10-fold increased over those following free LAQ824 or saline treatments and resulting in concordantly reduced levels of tumor ErbB2 mRNA. These preclinical results support the clinical evaluation of HDAC inhibitors against ErbB2-overexpressing malignancies, and further indicate that encapsulation into targeted and nontargeted liposomes substantially improves the in vivo pharmacokinetics, tumor uptake, and antitumor properties of hydroxamate-based HDAC inhibitors.
Collapse
MESH Headings
- Animals
- Area Under Curve
- Blotting, Northern
- Blotting, Western
- Capsules
- Cell Line, Tumor
- Cell Survival/drug effects
- Dose-Response Relationship, Drug
- Female
- Histone Deacetylase Inhibitors
- Histone Deacetylases/metabolism
- Humans
- Hydroxamic Acids/pharmacokinetics
- Hydroxamic Acids/pharmacology
- Hydroxamic Acids/therapeutic use
- Liposomes/immunology
- Mice
- Mice, Nude
- Neoplasms, Experimental/genetics
- Neoplasms, Experimental/prevention & control
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Rats
- Rats, Sprague-Dawley
- Receptor, ErbB-2/genetics
- Receptor, ErbB-2/immunology
- Receptor, ErbB-2/metabolism
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Daryl C Drummond
- Hermes Biosciences, Inc., South San Francisco, Buck Institute for Age Research, Novato, California 94945, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Andresen TL, Jensen SS, Jørgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 2005; 44:68-97. [PMID: 15748655 DOI: 10.1016/j.plipres.2004.12.001] [Citation(s) in RCA: 400] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Tumor specific drug delivery has become increasingly interesting in cancer therapy, as the use of chemotherapeutics is often limited due to severe side effects. Conventional drug delivery systems have shown low efficiency and a continuous search for more advanced drug delivery principles is therefore of great importance. In the first part of this review, we present current strategies in the drug delivery field, focusing on site-specific triggered drug release from liposomes in cancerous tissue. Currently marketed drug delivery systems lack the ability to actively release the carried drug and rely on passive diffusion or slow non-specific degradation of the liposomal carrier. To obtain elevated tumor-to-normal tissue drug ratios, it is important to develop drug delivery strategies where the liposomal carriers are actively degraded specifically in the tumor tissue. Many promising strategies have emerged ranging from externally triggered light- and thermosensitive liposomes to receptor targeted, pH- and enzymatically triggered liposomes relying on an endogenous trigger mechanism in the cancerous tissue. However, even though several of these strategies were introduced three decades ago, none of them have yet led to marketed drugs and are still far from achieving this goal. The most advanced and prospective technologies are probably the prodrug strategies where non-toxic drugs are carried and activated specifically in the malignant tissue by overexpressed enzymes. In the second part of this paper, we review our own work, exploiting secretory phospholipase A2 as a site-specific trigger and prodrug activator in cancer therapy. We present novel prodrug lipids together with biophysical investigations of liposome systems, constituted by these new lipids and demonstrate their degradability by secretory phospholipase A2. We furthermore give examples of the biological performance of the enzymatically degradable liposomes as advanced drug delivery systems.
Collapse
Affiliation(s)
- Thomas L Andresen
- Department of Chemistry, Technical University of Denmark, Building 207, DK-2800 Lyngby, Denmark.
| | | | | |
Collapse
|
17
|
Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol 2005; 391:40-57. [PMID: 15721373 DOI: 10.1016/s0076-6879(05)91002-1] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Vincristine is a dimeric Catharanthus alkaloid derived from the Madagascan periwinkle that acts by binding to tubulin and blocking metaphase in actively dividing cells. While vincristine is widely used in the treatment of a number of human carcinomas, its use is associated with dose-limiting neurotoxicity, manifested mainly as peripheral neuropathy. It is known that the therapeutic activity of vincristine can be significantly enhanced after its encapsulation in appropriately designed liposomal systems. Enhanced efficacy is also associated with a slight decrease in drug toxicity. Thus, the therapeutic index of vincristine can be enhanced significantly through the use of a liposomal delivery system. Vincristine may be encapsulated into liposomes of varying lipid composition by several techniques, including passive loading, pH gradient loading, and ionophore-assisted loading. However, most research has focused on the encapsulation of vincristine in response to a transbilayer pH gradient, which actively concentrates the drug within the aqueous interior of the liposome. This chapter details the preparation and evaluation of liposomal vincristine. Specifically, we elaborate on the components (choice of lipids, molar proportions, etc.), methods (preparation of liposomes, drug loading methods, etc.), critical design features (size, surface charge, etc.), and key biological endpoints (circulation lifetime, bioavailability, efficacy measurements) important to the development of a formulation of vincristine with enhanced therapeutic properties.
Collapse
Affiliation(s)
- Dawn N Waterhouse
- Department of Advanced Therapeutics, British Columbia Cancer Agency, British Columbia, Canada
| | | | | | | | | | | |
Collapse
|
18
|
Lundberg BB, Griffiths G, Hansen HJ. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J Control Release 2004; 94:155-61. [PMID: 14684279 DOI: 10.1016/j.jconrel.2003.09.016] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The ability to selectively target anti-cancer drugs via specific ligands against antigens expressed on malignant cells could greatly improve the therapeutic indices of the drugs. In this paper an anti-CD74 antibody (Ab), LL1, was covalently attached to the surface of sterically stabilized lipid drug-carriers (emulsions and liposomes) by use of a PEG-based heterobifunctional coupling agent. Target cells internalize LL1 very fast and that was found to be true for the LL1-lipid drug-carrier complexes as well. During a 24 h in vitro incubation with the target Raji B-lymphoma cells about 30% of the added complexes were associated with the cells. The corresponding value for drug-carrier without targeting ligand was near 0.6%. Displacement experiments showed that free LL1 competed well with LL1-complexes indicating preserved immunoreactivity. Non-target cells showed only unspecific association of LL1-complexes. A dioleoylated derivative of the anti-cancer drug 3',5'-O-dioleoyl-FUdR (FUdR) (FUdR-dO) loaded into LL1-lipid drug-carriers showed good cytotoxic activity. In vitro 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity tests against neoplastic B-cells gave IC30 values of 0.45, 1.25, 5.30 and 7.30 microM for the prodrug FUdR-dO in LL1-emulsions, LL1-liposomes, emulsions and liposomes, respectively. The value for the parent drug FUdR was calculated to 4.35 microM. In the light of the extensive and specific delivery of LL1-lipid drug-carriers to B-cells and the selective cytotoxicity of the incorporated drug, we infer that the complexes may be useful in the selective elimination of circulating malignant B-cells in vivo.
Collapse
Affiliation(s)
- Bo B Lundberg
- Department of Biochemistry and Pharmacy, Abo Akademi University, BioCity, PO Box 66, FIN-20521, Abo, Finland.
| | | | | |
Collapse
|
19
|
Abstract
Effective drug delivery requires the precise spatial and temporal delivery of therapeutic agents to the target site. To this end, a variety of chemical and physicochemical approaches have been devised to create lipid vesicles (liposomes) that can be triggered to release their contents in a controlled fashion. The triggers include changes in pH, redox potential, temperature, or the level of specific enzymes. We review the chemistries that have recently been applied to exploit the pH and redox potential triggers so as to release vesicle contents in the appropriate biological location.
Collapse
Affiliation(s)
- Xin Guo
- Department of Pharmaceutical Chemistry, University of California at San Francisco, 94143-0446, USA
| | | |
Collapse
|
20
|
Dan N. Effect of liposome charge and PEG polymer layer thickness on cell-liposome electrostatic interactions. BIOCHIMICA ET BIOPHYSICA ACTA 2002; 1564:343-8. [PMID: 12175916 DOI: 10.1016/s0005-2736(02)00468-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Targeted drug delivery requires binding to (and subsequent uptake by) the carrier and target cell. In this paper, we calculate the work required to bring into contact liposomal carriers and cells as a function of the liposome and cell electrostatic characteristics. We find that cell-liposome adhesion is sensitive to the cell type and optimized at a cell to liposome charge ratio which depends on the degree of cell charge regulation. As a result, uptake (which is dependent on the occurrence of binding) is also optimized. Incorporation of a (poly)ethylene glycol (PEG) layer enhances liposome adhesion in cases where the cell-liposome interactions are repulsive, and suppresses adhesion in systems where the interactions are attractive. Our results, which are in agreement with experimental observations, show that electrostatic interactions may be designed to enable targeted drug delivery by liposomes to a specific cell population.
Collapse
Affiliation(s)
- Nily Dan
- Department of Chemical Engineering, Drexel University, 3141 Chestnut St., Philadelphia, PA 19104, USA.
| |
Collapse
|
21
|
Almiñana N, Polo D, Alsina MA, Reig F. Optimization study of doxorubicin liposomal preparations coated with laminin fragments. Prep Biochem Biotechnol 2002; 32:1-16. [PMID: 11934073 DOI: 10.1081/pb-120013157] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Immunoliposomes, coated with two peptide sequences and loaded with doxorubicin, were prepared. The influence of different parameters in the sequential steps of liposomal preparations was studied as, for instance, lipid composition, size reduction methods, elimination of non-entrapped drug, and peptide coating sequence. Results were evaluated, such as entrapment efficiency, phospholipid/drug and phospholipid/peptide relationship, and size of final preparations. Effective size reduction was only achieved through probe sonication and the presence of peptides on the surface of liposomes, which does not modify, significantly, the final phospholipid/drug relationship, related to the initial values; however, they promoted a slight increase in the size of final preparations. Dialysis was the most suitable method to wash liposomes from reactants, drug and peptides, as well as being the cleanest process to avoid microbial contamination without significant dilution. Peptide coating yields were similar for liposomal compositions presenting free carboxyl groups on the surface. As determined by other authors, the presence of polyethylene glycol monomethoxy chains on the surface reduces the reactivity of NPGE carboxylic groups.
Collapse
|
22
|
Drummond DC, Hong K, Park JW, Benz CC, Kirpotin DB. Liposome targeting to tumors using vitamin and growth factor receptors. VITAMINS AND HORMONES 2001; 60:285-332. [PMID: 11037627 DOI: 10.1016/s0083-6729(00)60022-5] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Liposome-encapsulated anticancer drugs reveal their potential for increased therapeutic efficacy and decreased nonspecific toxicities due to their ability to enhance the delivery of chemotherapeutic agents to solid tumors. Advances in liposome technology have resulted in the development of ligand-targeted liposomes capable of selectively increasing the efficacy of carried agents against receptor-bearing tumor cells. Receptors for vitamins and growth factors have become attractive targets for ligand-directed liposomal therapies due to their high expression levels on various forms of cancer and their ability to internalize after binding to the liposomes conjugated to receptors' natural ligands (vitamins) or synthetic agonists (receptor-specific antibodies and synthetic peptides). This chapter summarizes various strategies and advances in targeting liposomes to vitamin and growth factor receptors in vitro and in vivo with special emphasis on two extensively studied liposome-targeting systems utilizing folate receptor and HER2/neu growth factor receptor.
Collapse
Affiliation(s)
- D C Drummond
- Liposome Research Laboratory, California Pacific Medical Center Research Institute, San Francisco 94115, USA
| | | | | | | | | |
Collapse
|
23
|
Affiliation(s)
- D C Drummond
- Research Institute, California Pacific Medical Center, 94115, San Francisco, CA, USA
| | | | | |
Collapse
|
24
|
Vodovozova EL, Moiseeva EV, Grechko GK, Gayenko GP, Nifant'ev NE, Bovin NV, Molotkovsky JG. Antitumour activity of cytotoxic liposomes equipped with selectin ligand SiaLe(X), in a mouse mammary adenocarcinoma model. Eur J Cancer 2000; 36:942-9. [PMID: 10785601 DOI: 10.1016/s0959-8049(00)00029-0] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The overexpression of lectins by malignant cells compared with normal ones can be used for the targeting of drug-loaded liposomes to tumours with the help of specific carbohydrate ligands (vectors). Recently we have shown that liposomes bearing specific lipid-anchored glycoconjugates on a polymeric matrix bind in vitro to human malignant cells more effectively and, being loaded with a lipophilic prodrug of merphalan, reveal higher cytotoxic activity compared with unvectored liposomes. In this study, carbohydrate-equipped cytotoxic liposomes were tested in vivo in a mouse breast cancer model, BLRB-Rb (8.17)1Iem strain with a high incidence of spontaneous mammary adenocarcinoma (SMA). Firstly, a cell line of the SMA was established which was then used to determine the specificity of the tumour cell lectins. After screening of the lectin specificity of a number of fluorescent carbohydrate probes, SiaLe(X) was shown to be the ligand with the most affinity, and a lipophilic vector bearing this saccharide was synthesised. Then different liposomal formulations of the synthetic merphalan lipid derivative and SiaLe(X) vector were prepared and applied in the treatment of mice with grafted adenocarcinomas. The results of the tumorigenesis data show that the therapeutic efficacy of merphalan increases sharply after its insertion as a lipophilic prodrug into the membrane of SiaLe(X)-vectored liposomes.
Collapse
Affiliation(s)
- E L Vodovozova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow, Russia
| | | | | | | | | | | | | |
Collapse
|
25
|
Harvie P, Wong FM, Bally MB. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci 2000; 89:652-63. [PMID: 10756331 DOI: 10.1002/(sici)1520-6017(200005)89:5<652::aid-jps11>3.0.co;2-h] [Citation(s) in RCA: 119] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
We evaluated the use of poly(ethylene glycol) (PEG)-modified lipids to control the surface properties of a lipid-based gene transfer system. The lipid-DNA particles (LDPs) used form spontaneously when plasmid DNA is added to mixed detergent lipid micelles consisting of the non-ionic detergent n-octyl-D-glucopyranoside, the cationic lipid dioleyldimethylammonium chloride (DODAC), the zwitterionic lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and selected PEG-modified phosphatidylethanolamines. The inclusion of DODAC is required to form the hydrophobic lipid-DNA complex. DOPE is included to facilitate dissociation of DNA from the cationic lipid and the PEG-modified lipids are added in an effort to stabilize the surface attributes of the resulting lipid-DNA particles. We used PEG-lipids that varied in acyl chain composition because of recent results demonstrating acyl chain dependent transfer of PEG-lipids from lipid vesicles, providing the potential to allow a transformation of the surface properties due to loss of surface grafted PEG. The addition of PEG-modified lipids does not interfere in LDP formation and its presence favors formation of smaller particles (75 nm in contrast to 130 nm in the absence of the PEG-modified lipid). PEG-lipid incorporation causes a concentration dependent reduction in LDP-mediated transfection of B16/BL6 melanoma cells, a result that can be partially attributed to a reduction in particle binding to cells. However, significant LDP binding to B16/BL6 cells was still observed under conditions where LDP transfection activity was reduced by more than 85%. The potential for PEG to interfere with LDP processing following cell binding is discussed.
Collapse
Affiliation(s)
- P Harvie
- Department of Advanced Therapeutics, British Columbia Cancer Agency, 601 West 10th Ave., Vancouver, B.C., V5Z 1L3, Canada
| | | | | |
Collapse
|
26
|
Mastrobattista E, Koning GA, Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 1999; 40:103-127. [PMID: 10837783 DOI: 10.1016/s0169-409x(99)00043-5] [Citation(s) in RCA: 139] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
This review presents an overview of the field of immunoliposome-mediated targeting of anticancer agents. First, problems that are encountered when immunoliposomes are used for systemic anticancer drug delivery and potential solutions are discussed. Second, an update is given of the in vivo results obtained with immunoliposomes in tumor models. Finally, new developments on the utilization of immunoliposomes for the treatment of cancer are highlighted.
Collapse
Affiliation(s)
- E Mastrobattista
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Pharmacy, Utrecht University, Sorbonnelaan 16, 3508 TB, Utrecht, The Netherlands
| | | | | |
Collapse
|